MLMintao Lin

Mintao Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mintao Lin has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Shengchun Huang

    Department of Laboratory Medicine, Foshan Hospital of Traditional Chinese Medicine, The Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan, Guangdong, China

    1 shared publication
  • Xueya Zhuo

    Department of Clinical Laboratory, Foshan Hospital of Traditional Chinese Medicine, Foshan City, China

    1 shared publication
  • Yan Huang

    Department of Clinical Laboratory, Foshan Hospital of Traditional Chinese Medicine, Foshan City, China

    1 shared publication

Latest Publications

  • Open Access

    Predictive value of suPAR in AKI: a systematic review and meta-analysis

    by Yan Huang, Shengchun Huang, Xueya Zhuo, Mintao Lin

    Background Some clinical trials have shown that soluble urokinase-type plasminogen activator receptor (suPAR) has good predictive value for acute kidney injury (AKI), but there is still a lack of evidence-based proof. Therefore, we conducted this systematic review and meta-analysis to evaluate the predictive value of suPAR for AKI. Methods Pubmed, EMBASE, Cochrane Library, and Web of Science databases were searched until December 2021 to obtain the literature on the prediction of suPAR for AKI. The quality of the included studies was assessed using the QUADAS-2 scoring system, and a bivariate random-effect model was used for the meta-analysis. The present study has been registered on PROSPERO (Registration No. CRD42022324978). Results Seven articles were included, involving 2,319 patients, 635 of whom were AKI patients. The meta-analysis results showed that the combined sensitivity of suPAR in predicting AKI was 0.77 (95% CI 0.67–0.84); the specificity was 0.64 (95% CI 0.53–0.75); the odds ratio of diagnosis was 6 (95% CI 3–10); the pooled positive likelihood ratio was 2.2 (95% CI 1.6–2.9); the pooled negative likelihood ratio was 0.36 (95% CI 0.26–0.52); and the area under the summary receiver-operating characteristic (SROC) curve was 0.77 (95% CI 0.12~0.99). Deek’s funnel plot suggested no potential publication bias among included studies. Conclusion suPAR is a valuable biomarker for the prediction of AKI with relatively high predictive accuracy, but its clinical application needs improvements. SuPAR should be considered as an indicator in the subsequent development of more effective predictive tools for AKI.